PDL-1 monoclonal antibody, Avelumab was studied in a phase 1 trial (JAVELIN Hodgkin) in patients with relapsed/refractory cHL which showed an ORR of ~42% with CR in 19.4% patients (41). Here, CD274 is linked to classic Hodgkin lymphoma.